Sanofi (NASDAQ:SNY) Reaches New 52-Week Low – Time to Sell?

Sanofi (NASDAQ:SNY)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $42.78 and last traded at $42.8140, with a volume of 2598798 shares traded. The stock had previously closed at $43.31.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of research analyst reports. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. Weiss Ratings cut Sanofi from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 29th. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Citigroup reiterated a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Finally, BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target for the company. in a report on Monday, April 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $51.00.

Sanofi Trading Down 1.9%

The company has a market cap of $103.66 billion, a P/E ratio of 11.87, a PEG ratio of 1.07 and a beta of 0.35. The business has a fifty day moving average price of $46.17 and a 200-day moving average price of $47.76. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th will be issued a dividend of $2.4225 per share. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a dividend yield of 559.0%. The ex-dividend date is Monday, May 4th. Sanofi’s dividend payout ratio is presently 49.44%.

Institutional Investors Weigh In On Sanofi

Institutional investors have recently made changes to their positions in the company. Flagship Harbor Advisors LLC bought a new stake in shares of Sanofi during the fourth quarter worth approximately $25,000. Physician Wealth Advisors Inc. boosted its holdings in shares of Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after acquiring an additional 379 shares during the period. Leonteq Securities AG boosted its holdings in shares of Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after acquiring an additional 297 shares during the period. Measured Wealth Private Client Group LLC bought a new stake in shares of Sanofi during the third quarter worth approximately $29,000. Finally, Palisade Asset Management LLC bought a new stake in shares of Sanofi during the third quarter worth approximately $30,000. Institutional investors own 14.03% of the company’s stock.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.